Board of Directors

Green Biologics’ Board of Directors includes:


Simon became Chairman of GBL in December 2013. Following a successful career with Goldman Sachs, Simon now manages an international portfolio of private and public equity, bonds and venture capital investments through his firm, SM Investments. He also provides consultancy and board services to a number of companies. Simon was a Partner at Goldman Sachs where he was co-head of the European Special Situations Group (ESSG), responsible for proprietary investments including a large portfolio of turnaround, venture capital and private equity investments, throughout Europe, Middle East and Africa. Simon joined Goldman Sachs in 1999 to set up a broker-dealer of distressed bank debt and bonds. In 2003 he co-founded the ESSG. During his earlier career, Simon worked as a managing director for Bankers Trust Company heading up distressed trading in Asia and Japan. Simon earned a degree in civil engineering from Fitzwilliam College, Cambridge University.


Sean Sutcliffe has served as Chief Executive of Green Biologics since April 2008, contributing to the company extensive commercial and operational experience across the energy and renewables sector. Prior to joining Green Biologics he was from 2005 Chief Executive of Biofuels Corporation, a UK based biodiesel producer, and from 2007 Chairman of Tidal Generation Limited, a developer of tidal stream devices. Previously Sean worked for BG Group Plc. for 14 years in a variety of roles spanning operations, business development and strategy, most recently as Executive Vice President with responsibility for Corporate Development and New Businesses. Sean is a Chartered Mechanical Engineer with an Engineering degree from Cambridge University and is a Non-Executive Director of You Broadband, an Indian ISP.

David is an Operating Partner with Oxford Capital Partners, who led GBL's Series A round of financing. He has more than 20 years of investment experience including venture capital and private equity, including 14 years in biotechnology venture capital. Following 11 years at 3i Group plc leading a broad range of transactions, David was Chief Business Officer and Executive Committee Member of Evotec AG and Chairman of The Mabey Group. David is currently the Chairman of Crysalin Ltd, Optimal Medicine Ltd, and HealthiQ Limited. He holds a B.Sc. degree, with honors, in Genetics and Zoology from Sheffield University in the UK.

James Hohman retired from OMNOVA Solutions in 2014 following a long career as President of OMNOVA Solutions’ Performance Chemicals business unit and a corporate Senior Vice President of OMNOVA. Prior to joining OMNOVA/Gencorp, Jim held key general management, business and marketing management positions with BP Chemicals and B.F. Goodrich. Jim is also a board member of Pilot Chemical Company. In his 19 years at OMNOVA and GenCorp, Jim was instrumental in broadening the company’s global reach in emulsion polymers and specialty chemicals to include applications around the world in oil and gas, construction, high performance coatings, nonwovens, adhesives, automotive, polymer and rubber modification, antioxidants, coated paper and packaging, carpet and flooring, and others. At OMNOVA/Gencorp, Jim led negotiations for a number of acquisitions including the Goodyear/Calhoun, Georgia latex facility, the U.S. specialty chemicals businesses of Sequa Chemicals and PolymerLatex, and the acquisition of ELIOKEM, a key acquisition that significantly broadened OMNOVA’s served markets and expanded the company’s global manufacturing footprint. Jim holds a bachelor of science degree in Honors Chemistry from The Ohio State University and an MBA from the University of Louisville.

Maggie Leung is the General Manager of Environmental Services of Swire Pacific Limited, overseeing the portfolio of green technological companies that Swire has made minority investments. In addition, she is responsible for the administration of the two Swire’s joint venture companies on the waste management industry. Maggie has been with the Swire Group for over 17 years, predominantly working in the aviation field. She also spent 3 years in Hong Kong Express Airways, where she took a leading role in starting up the airline. Maggie holds a MBA from the Cardiff University, UK and has completed advanced management programmes at INSEAD, France and at Tsinghua University, PRC.

Denis Lucquin is a Managing Partner and Chairman of Sofinnova Partners, specializing in industrial biotechnology investments. He joined Sofinnova in 1991. Denis began his career in academic research. For five years, he was in charge of the technology transfer department at the Institut National de la Recherche Agronomique (INRA), France’s agricultural research institute. In 1989, he joined the venture capital industry as director of investments at Innolion (Crédit Lyonnais). He has invested in and participated as a board member with numerous European investments including Nicox, Oxford Glycosciences, Oxford Molecular, PPL Therapeutics, Conjuchem, Exonhit, IDM, Innate Pharma, and Ablynx (all of which successfully went public) as well as Novexel (sold to Astrazeneca), Crop Design, Cerenis, and Noxxon. He most recently invested in BioAmber and Green Biologics, developers of bio-sourced molecules for the chemical industry, and in Avantium, a renewable chemicals company developing biobased plastic bottles for food and beverage. Denis is a founder of the France Biotech Association. He is a graduate in engineering from Ecole Polytechnique and Ecole du Génie Rural des Eaux et Forêts. He has a degree in Innovation Management from the Université de Paris-Dauphine.

Claude is Senior Investment Manager for Capricorn Venture Partners since 2000 and a Partner from mid-2013. He is also a Senior Investment Manager for Capricorn's Cleantech Fund, who led GBL's Series B round of financing. Prior to joining Capricorn, Claude held management positions with FMC Corp, Occidental Chemical, PA Technology and Akzo / Fabelta. Claude serves or has served at the Board of Directors of BioAlliance, Elbion / 4AZA, TiGenix, UroGene, Fluxome, FlandersBio vzw, Fluxome, Alaska Food Diagnostics, Avantium, FRX Polymers, Green Biologics, Capricorn Venture Fund II and Capricorn Cleantech Fund. Claude holds an M.Sc. in Chemistry from the University of Brussels and is a graduate in Business Administration and International Trade from the University of Brussels.